< Back to latest news & events

News

Latest CRISPR patent dispute

June 2019

HGF Patent Director and established CRISPR expert Catherine Coombes comments in The Scientist and Science Magazine within hours of recent CRISPR dispute.

The Scientist

USPTO restarts CRISPR Patent dispute between broad and UC

The US patent office declares an interference between the intellectual property held by the Broad Institute and several patent applications filed by the University of California – opposite its previous ruling. The legal battle over the intellectual property surrounding CRISPR gene editing technology is not over. The US Court of Appeals for the Federal Circuit ruled last September that patents held by the Broad Institute of MIT and Harvard University were not in conflict with previously submitted patents from the University of California (UC), Berkeley. But the US Patent and Trade mark Office (USPTO) has now posted documents declaring interference between them—meaning they may cover overlapping IP.

“Certainly, this new patent interference in the US adds to the complexity of the landscape,” Catherine Coombes, a patent director with HGF Limited in the UK who represents CRISPR patent holders in Europe, writes in an email to The Scientist.

Click here for the full article.

Science Magazine

Surprise patent ruling revives high-stakes dispute over the genome editor CRISPR

The high-profile patent fight over who invented a key feature of the genome editor CRISPR has been resurrected. The 3-year-old battle, which a U.S. appeals court appeared to have put to rest in September 2018, pits parties represented by the University of California (UC) against the Broad Institute of Cambridge, Massachusetts. It revolves around the use of CRISPR, originally derived from a DNA-cutting system used by bacteria, in the more complex cells of eukaryotes, which includes humans, making the contested patents key to the potentially lucrative development of novel medicines.

Catherine Coombes, a patent attorney at HGF in York, U.K., who does not represent Broad or UC but is involved in CRISPR patents, says the new interference “adds to the complexity of the landscape.” The European Patent Office has grated “overlapping rights” to both groups and others who have filed CRISPR patent applications, anticipating that legal fights will occur later. “For human therapeutics, it is still too early to know where the key patents will lie,” Coombes says, noting that different enzymes used in various CRISPR systems ultimately may make one invention safer or more effective than another.

Click here for the full article.

Latest updates

Fashionably IP - podcast exploring hot topics in the world of fashion and intellectual property

We are delighted to launch our new Fashionably IP Podcast were we will be looking at important hot topics in the world of fashion and intellectual property. In the podcast, …

Read article
Event - 24th June 2022

pro-manchester Trailblazing Tech Conference 2022

pro-manchester is hosting their Trailblazing Tech Conference 2022 on Friday 24th June. At this event, speakers and attendees will be discussing developments in fintech and cyber security, analysing the impact …

Event details

HGF ranked Gold in the FT special report – Europe’s Leading Patent Law Firms 2022

HGF has been ranked in the ‘Gold’ and ‘Silver’ bands in The Financial Times special report ‘Europe’s Leading Patent Law Firms’ published on the 16th June 2022. More than 10,000 …

Read article